The microtubule-associated protein tau accumulates into toxic aggregates in multiple neurodegenerative diseases. We found previously that loss of D2-family dopamine receptors ameliorated tauopathy in multiple models including a Caenorhabditis elegans model of tauopathy.
Introduction
Tauopathies are neurodegenerative diseases characterized by the toxic accumulation of abnormal conformers of the microtubule-associated protein tau (1) . Alzheimer's disease and frontotemporal lobar degeneration (FTLD) are the most commonly occurring tauopathies (2) . Various clinical strategies are being pursued to reduce tau toxicity, including reducing tau phosphorylation, tau cleavage, tau fibrillization, and tau expression levels (2) . However, many candidate therapies have issues of non-specificity and safety. There are currently no treatments that halt or reverse the accumulation of pathological tau in human patients (2) .
We previously identified D2-like receptor antagonist drugs ameliorating tauopathy phenotypes using a whole animal Caenorhabditis elegans model of tau toxicity (3) .
Pan-neuronal expression of human tau in C. elegans causes neurotoxicity, including a significant accumulation of tau aggregates, behavioral dysfunction, progressive neuron loss, and shortened lifespan (4) . We demonstrated that loss of dop-2 and dop-3, the two D2-like dopamine receptors in C. elegans, significantly ameliorated tau-induced toxicity in tau transgenic C. elegans (3) . Multiple studies have shown that overexpression of tau alters dopamine signaling by causing loss of dopaminergic neurons (5) (6) . In addition, activation of D1 dopamine receptors has been shown to increase tau phosphorylation (7) . One study addressed how blocking D2-family dopamine receptors may suppress tauopathy using the D2 antagonist haloperidol (8); however, this drug is not specific to dopamine receptors (9). Therefore to better understand how loss of D2-like dopamine receptors suppresses tauopathy phenotypes, we performed a genetic screen of dopamine-related genes in tau transgenic C. elegans. We identified bas-1, the C. 
Lifespan analysis
Lifespan assays were performed as described previously (11) with a few modifications. 100-150 L4 stage worms per strain were transferred to 35 mm NGM plates (25 worms/plate) seeded with 75 µL of 10X OP50 Escherichia coli and 0.05 mg/mL fluorodeoxyuridine (FUdR). Worms were maintained at 25°C. Dead worms were counted every day. A worm was considered dead when it did not respond to repeated poking by a platinum wire. Worms that crawled off the plate or died from unusual causes were censored from analysis.
Neurodegeneration assays
tgT337;unc-47::GFP and tgT337;unc-47::GFP;bas-1(ad446) worms were synchronized by timed egg lays. Worms were mounted on 2% agarose pads containing 0.1% sodium azide as a paralytic at 4 or 7 days of age. The number of GABAergic neurons in the ventral nerve cord were counted with a DeltaVision microscope (Applied Precision) using 60X magnification. Twenty animals were counted per strain per time point.
Immunoblotting
Protein samples were diluted with 5x sample buffer (0.046 M Tris, 0.005 M EDTA, 0.2 M dithiothreitol, 50% sucrose, 5% sodium dodecyl sulfate, 0.05% bromophenol blue), boiled for 5 min., and centrifuged at 13,000 x g for 5 min. prior to being loaded onto 4-15% pre-cast Criterion sodium dodecyl sulfate polyacrylamide gel electrophoresis gradient gels and transferred to PVDF membranes as recommended by the manufacturer (Bio-Rad). 5-10 µL of diluted sample was loaded for each analysis. Primary antibodies used were rabbit monoclonal anti-tau antibody (Rockland) at 1:5000, mouse anti-phospho-tau antibody CP13 (Peter Davies) at 1:1000, mouse anti-phosphotau antibody PHF-1 (Peter Davies) at 1:1000, rabbit anti-phospho-tau antibody pS422 (Abcam) at 1:500, goat anti-GFP antibody (Rockland) at 1:5000, and mouse anti-tubulin antibody E7 (Developmental Studies Hybridoma Bank) at 1:5000. Secondary antibodies used were anti-rabbit HRP (Jackson Immuno Research), anti-mouse HRP (Jackson Immuno Research), and anti-goat HRP (Rockland), all at 1:5000. ECL substrate (Bio-Rad) was added to the membrane and chemiluminescence signals were detected with ChemiDoc-It Imager (UVP) and measured with UVP Software.
Tau protein extraction
Staged young adult tau transgenic C. elegans were grown from eggs at 20°C for 3 days on 5XPEP plates, washed off plates in M9 buffer, and collected by centrifugation.
Worms were snap frozen in liquid nitrogen and stored at -70°C. Tau fractions were obtained as described previously (4). 2 µL of RAB Hi-Salt buffer (0.1 M MES, 1 mM EGTA, 0.5 mM MgSO 4 , 0.75 M NaCl, 0.02 M NaF, pH 7.0) containing PMSF and protease inhibitors was added per mg of worm pellet and homogenized by sonication. A portion of the sample was saved for immunoblotting while the rest was centrifuged at 40,000 x g for 40 min. The supernatant was the RAB/soluble fraction. The pellet was extracted by adding 1 µL of RIPA buffer (50 mM Tris, 150 mM NaCl, 1% Nonidet P-40, 5 mM EDTA, 0.5% deoxycholate, 0.1% SDS, pH 8.0) containing PMSF and protease inhibitors per mg of original worm pellet weight and centrifuged at 40,000 x g for 20 min. 
Catecholamine measurements
Staged young adult C. elegans were grown from eggs at 20°C for 3 days on 5XPEP plates, washed off plates in M9 buffer, and collected by centrifugation. ~150 µL of packed worms were snap frozen in liquid nitrogen and stored at -70°C. Pellets were extracted with 0.1M perchloric acid. 50 µl was used for Pierce BCA protein determination. The remainder was centrifuged and the supernatant frozen at -70°C until assayed. The acid extract was put through an alumina extraction procedure before injection onto HPLC. Catecholamine levels were measured using electrochemical detection by a Dionex Choulochem III HPLC system. The data was analyzed using the 
Results

Identification of dopamine-related genes involved in tauopathy phenotypes.
Previous work in our lab demonstrated that the combined loss of dop-2 and dop-3, D2like dopamine receptors, suppresses tauopathy phenotypes in our C. elegans tauopathy model (3). D2-like dopamine receptors are G-protein coupled receptors that activate G i/o -mediated signaling pathways and also act presynaptically to regulate dopamine release (12). Therefore, we crossed tau transgenic C. elegans with strains containing loss of function alleles in dopamine-related genes including genes involved in dopamine synthesis, metabolism, and downstream signaling (Table S1 ). We assayed the resulting strains for behavioral deficits using liquid thrashing assays, which measure C. elegans responses to immersion in liquid (Table S2) . A few genes significantly modulated the swimming response of tau transgenic worms ( Table 1) . Most of these genes enhanced the tau-induced behavioral deficit. However, these enhancers of tau toxicity also caused significant impairment of locomotion in wildtype animals that do not carry the tau transgene, demonstrating that they influence behavior independent of tau.
Loss of DOPA decarboxylase suppresses tau-induced behavioral dysfunction.
bas-1, the C. elegans gene for DOPA decarboxylase (DDC), was the only suppressor of tau related phenotypes identified in our screen. We tested two independent deletion alleles of bas-1, ad446 and tm351, which both rescued the behavioral dysfunction of tau transgenic C. elegans without altering behavior in wild-type C. elegans ( Figure 1A (Table S3 ). The allele ad446 additionally deletes basl-1, a gene predicted to encode a nonfunctional paralog of DDC (13). We assayed the effect of deleting basl-1 alone by examining basl-1(ok703) and found it did not alter the behavior of tau transgenic C. elegans ( Table S2 ).
Loss of DOPA decarboxylase decreases tau phosphorylation
Phosphorylation of tau is a normal mechanism for regulation of tau activity, but hyperphosphorylation of tau, commonly seen in tauopathies, is thought to be toxic and precede the formation of insoluble aggregates (14). We examined whether loss of bas-1 modulated total tau levels or tau phosphorylation in tau transgenic C. elegans. We assessed tau phosphorylation with three different antibodies against phosphorylated tau: CP13 (pSer202), PHF-1 (pSer396/pSer404), and pSer422 (15). Phosphorylation of tau at these three sites is elevated in Alzheimer's disease patient brains (16). Loss of bas-1 did not alter total tau levels significantly but generally reduced the phosphorylation at all three sites probed ( Figure 1C ; Table 2 ).
Loss of DOPA decarboxylase decreases tau aggregation
The deposition of detergent insoluble aggregates of tau protein is a hallmark of human tauopathies (2) . Detergent insoluble tau increases in tau transgenic C. elegans with age and with disease-causing mutations in tau (4). To determine whether loss of bas-1 affected the pathological aggregation of tau, we subjected tau transgenic C. elegans M A N U S C R I P T
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Kow RL et al 11 with or without bas-1 null alleles to extraction with buffers of increasing solubilizing strength. We found that loss of bas-1 did not change tau levels in soluble (RAB) fractions but reduced tau in detergent-soluble (RIPA) and detergent-insoluble (FA) fractions ( Figure 1D ; Table 2 ).
Loss of DOPA decarboxylase rescues neurodegeneration, but not longevity of tau transgenic C. elegans.
Neuronal loss occurs during the brain organ failure that causes premature death in tauopathy patients. Progressive neuronal loss and shortened lifespan are phenotypes seen in this tau transgenic C. elegans model (4). To determine whether loss of bas-1 affected the neurodegenerative phenotype seen in C. elegans, we crossed tau transgenic C. elegans carrying the bas-1 allele ad446 with the transgenic strain EG1285. EG1285 carries a GFP reporter transgene (Punc-47::GFP) which marks the cell bodies and processes of motor neurons within the ventral nerve cord of C. elegans (17). The resulting strain carries the bas-1 null allele, the tau transgene, and the GFP reporter. We counted the number of GABAergic motor neurons and observed a significant rescue of degenerating GABAergic neurons in bas-1 mutants at both 4 and 7 days of age ( Figure 2 ).
Tau transgenic C. elegans have shortened lifespans when compared to WT worms (4). However, we previously found that azaperone, a chemical suppressor of tau toxicity in tau transgenic C. elegans, was unable to extend lifespan (3) . Similarly, loss of bas-1 did not extend lifespan significantly in tau transgenic C. elegans ( Figure S2 ; Table   S4 ).
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Overexpression of DOPA decarboxylase worsens tau-induced phenotypes.
Since loss of DDC gene bas-1 suppresses tau toxicity in our tau transgenic C. elegans, we investigated whether overexpression of BAS-1 protein would modulate tau toxicity.
We crossed tau transgenic C. elegans with two different strains overexpressing BAS-1 fused to GFP under the bas-1 promoter (Pbas-1::bas-1::gfp). Overexpression of BAS-1::GFP fusion protein has been shown to rescue age-dependent decreases in serotonin and dopamine levels in C. elegans, suggesting that the GFP fusion does not interfere with BAS-1 protein activity (18). We found significant enhancement of the tau-induced behavioral dysfunction with overexpression of BAS-1 ( Figure 3A -C). However, overexpressing BAS-1 impaired the behavior of wild-type C. elegans to a similar extent.
This suggests that overexpression of BAS-1 may induce behavioral dysfunction independently of tau.
Enzymes upstream of DOPA decarboxylase are required for suppression of tauinduced phenotypes.
DDC catalyzes the second step in the dopamine and serotonin synthesis pathways.
Loss of DDC gene bas-1 significantly reduces dopamine and serotonin levels in C.
elegans (18-20). Loss of function in the genes encoding tyrosine hydroxylase (cat-2) or tryptophan hydroxylase (tph-1) causes significant reduction in dopamine or serotonin levels respectively (20-21), but neither had an effect on tau-induced behavior dysfunction (Table S2 ). In addition, loss of cat-4 or cat-1, two other genes that regulate (Table S2 ). One way loss of bas-1 could suppress tau-induced toxicity is via accumulation of dopamine and serotonin synthesis intermediates L-DOPA and 5-hydroxytryptophan (5-HTP). Accumulation of these intermediates requires the activity of upstream enzymes tyrosine hydroxylase and tryptophan hydroxylase. Thus, to test whether suppression of tau by loss of DDC is modulated by upstream enzymatic activity, we generated tau transgenic C. elegans carrying the bas-1 null allele ad446 and a loss of function allele in cat-2, tph-1, or cat-4. We compared the behavior of these strains to that of tau transgenic C. elegans (tgT337) and to tau transgenic C. elegans carrying the bas-1 null allele (tgT337;bas-1(ad446)) ( Figure 3D ; Table S5 ).
Loss of cat-2 should decrease L-DOPA synthesis but not affect 5-HTP synthesis.
We found that tau transgenic C. elegans carrying null alleles in both bas-1 and cat-2 still had significantly improved behavior compared to tau transgenic C. elegans but were significantly worse than tau transgenic C. elegans only carrying a null allele in bas-1, suggesting loss of cat-2 partially blocked suppression of tau by loss of bas-1.
Similarly, loss of tph-1 should decrease 5-HTP synthesis but not affect L-DOPA synthesis. We found that tau transgenic C. elegans carrying null alleles in both bas-1 and tph-1 had significantly improved behavior compared to tau transgenic C. elegans but were significantly worse than tau transgenic C. elegans only carrying a null allele in bas-1, suggesting that loss of tph-1 also partially blocks tau suppression by loss of bas-
1.
Loss of cat-4 should decrease both L-DOPA and 5-HTP synthesis.
Tetrahydrobiopterin is a cofactor for aromatic amino acid hydroxylases such as tyrosine hydroxylase and tryptophan hydroxylase and cat-4 encodes the C. elegans gene for M A N U S C R I P T
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Kow RL et al 14 GTP cyclohydrolase, the first enzyme in tetrahydrobiopterin synthesis (23). We found that tau transgenic C. elegans carrying loss of function alleles in both bas-1 and cat-4 had similar behavior dysfunction as tau transgenic C. elegans. This suggests that loss of cat-4 completely blocks the suppression of tau toxicity by loss of bas-1. Because loss of cat-4 reduced the L-DOPA accumulation in bas-1 null C. elegans to the same extent as loss of cat-2 (Table S3 ), loss of cat-4 does not block suppression of tau toxicity by bas-1 solely through lowering L-DOPA but must involve other molecular mechanisms.
Loss of DOPA decarboxylase and loss of D2-like dopamine receptors suppress tau-induced behavior via a shared mechanism
We initially tested bas-1 and other dopamine-related genes due to the fact that loss of D2-like dopamine receptor genes suppressed tau-induced toxicity in tau transgenic C. elegans (3) . To see if loss of DDC and loss of D2-like dopamine receptors suppress tau via a shared mechanism, we created tau transgenic C. elegans with loss of function alleles in bas-1, dop-2 and dop-3. We compared the behavior of tau transgenic C. elegans with loss of bas-1 only, tau transgenic C. elegans with loss of dop-2 and dop-3, and tau transgenic C. elegans with loss of bas-1, dop-2, and dop-3 ( Figure 3E ; Table   S6 ). We found that all three strains exhibited significantly suppressed tau-induced toxicity, but there was no significant additive suppression of tauopathy in animals carrying all three dopamine pathway mutations. This indicates that bas-1 and dop-2/dop-3 suppression of tauopathy share a common signaling mechanism.
Discussion
We have used our transgenic C. elegans model of tau toxicity to evaluate dopaminerelated genes in the genesis of tauopathy phenotypes. In this screen, we found several candidate enhancers of tau mediated behavioral phenotypes, but none appeared to specifically modify tauopathy. We identified bas-1, the C. elegans homolog of DOPA decarboxylase (DDC), as a suppressor of tau toxicity in C. elegans. We found that loss Regardless, the enhancers we identified included genes whose human homologs have been reported to modulate tau including tax-6 (human homolog PPP3CC) and Table S3 ). Our results indicate that loss of dopamine and serotonin cannot be the mechanism of suppression because loss of function mutations in other genes required for their biosynthesis did not suppress tau-induced toxicity.
Our results support a possible mechanism for suppression of tau toxicity by the combined accumulation of L-DOPA and 5-HTP ( Figure 4 ). Loss of cat-2, the C. elegans gene for tyrosine hydroxylase, only reduces levels of L-DOPA and not 5-HTP. indicating that DDC and D2 family dopamine receptors share a mechanism for suppression of tau. Interestingly, pharmacological agents that inhibit D2 receptors or antisense RNA against D2 receptors have been shown to increase DDC activity in rodents (35). This is the opposite of what we would expect based on our data. However, constitutive loss of D2 family dopamine receptors might have different effects on DDC activity in C. elegans compared to short-term or pharmacological loss of D2 family dopamine receptor activity in rodents.
In conclusion, we have identified bas-1, the C. elegans homolog of DOPA decarboxylase (DDC), as a suppressor of tau toxicity in our transgenic C. elegans model of tauopathy. While we have determined that upstream enzymatic activity by tyrosine hydroxylase and tryptophan hydroxylase are necessary for observing the full suppression by DDC, the mechanism of tau suppression is still unclear. Since loss of bas-1 reduced phosphorylation of tau, there are likely kinases or phosphatases modulated by loss of bas-1 function; further study will be needed to identify them. In addition, further translational studies exploring whether loss of DDC suppresses tau toxicity in the mammalian brain will be required to understand whether DDC could serve as a point of intervention in authentic human tauopathy disorders. 105% (p=0.11) 98% (p = 0.61) 254% (p = 9.1E-21) 202% (p = 7.6E-11) egl-8 [PLCB1] n488 (deletion) sa47 (Q85Stop) 42% (p = 1.5E-10) 67% (p = 6.2E-16) 32% (p = 3.2E-5) 51% (p = 3.0E-5) egl-10 [RGS] n692 (W418Stop) 9% (p = 5.9E-10) 8% (p = 1.5E-4) grk-2 [GRK2] gk268 (deletion) 30% (p = 1.4E-51) 50% (p = 5.6E-5) unc-43 [CAMK2D] n1186 (Q67Stop) n498 x (E108K) 29% (p = 6.0E-10) 5% (p = 1.2E-6) 23% (p = 5.0E-10) 28% (p = 6.5E-4) tax-6 [PPP3CC] p675 (D259N) 34% (p = 2.5E-4) 38% (p = 4.7E-3)
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Motor function was assessed via liquid thrashing assays. C. elegans carrying the mutation alone were compared to N2 (wild-type) C. elegans, while C. elegans strains carrying the mutation and the tau transgene were compared to tau transgenic C. elegans. At least 15 animals were assessed per strain and Student's t-tests were used to determine significance. Kow RL et al   27   Table 2 . Effect of bas-1 alleles on tau levels.
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Comparison to tgT337 levels tgT337;bas-1(ad446) tgT337;bas-1(tm351) total tau/tubulin (n = 6) 88% (S.E.M. 9%; p = 0.88) 125% (S.E.M. 23%; p = 0.88) RAB (soluble) tau/total tau (n = 5) 99% (S.E.M. 14%; p = 1) 107% (S.E.M. 29%; p = 1) RIPA (detergent soluble) tau/ total tau (n = 5) 43% (S.E.M. 10%; p = 0.01) 76% (S.E.M. 16%; p = 0.26) FA (detergent insoluble) tau/ total tau (n = 5) 44% (S.E.M. 13%; p = 0.07) 39% (S.E.M. 20%; p = 0.05) CP13 tau/total tau (n = 5) 52% (S.E.M. 8% p = 0.02) 55% (S.E.M. 7% p = 0.01) PHF-1 tau/total tau (n = 5) 71% (S.E.M. 8% p = 0.04) 76% (S.E.M. 14% p = 0.10) pS422/total tau (n = 4) 31% (S.E.M. 8% p = 0.04) 53% (S.E.M. 15% p = 0.39)
For each replicate, the measured chemiluminescence signals were normalized to that for tau transgenic alone (tgT337). 4-6 replicates were used for each analysis. Data was analyzed by Kruskal-Wallis with post-hoc Dunn's multiple comparisons used to determine significance. [B] Effect of bas-1(tm351) on liquid thrashing rate of tgT337 worms. 4-day-old C. elegans were placed in M9 buffer and thrashes were counted for 1 minute. Experiments were performed 5 times for a total of 100 worms per group. Data is displayed as mean ± standard error (S.E.M.). Student's ttest was used to compare tgT337 to tgT337;bas-1 worms. **** p = 9.1E-21 for ad446 and 7.6E-11 for tm351.
[C] Effects of bas-1 alleles on phosphorylation of tau in tau transgenic C. elegans. Representative immunoblots for tau phosphorylation at different sites. CP13 detects phosphorylation at Ser202. PHF-1 detects phosphorylation at Ser396/Ser404. pS422 detects phosphorylation at Ser422.
[D] Effects of bas-1 alleles on tau solubility in tau transgenic C. elegans. Representative immunoblots for tau after sequential extraction of tau transgenic worms (tgT337) and bas-1 mutants (tgT337;bas-1(ad446) and tgT337;bas-1(tm351)). Total tau is tau in lysates prior to sequential extraction. The RAB fraction is soluble tau, the RIPA fraction is detergent soluble tau, and the formic acid (FA) fraction is detergent insoluble tau. Tubulin was used as a load control. Chemiluminscence signals were quantified for 4-6 replicates by Kruskal-Wallis with post-hoc Dunn's multiple comparisons to determine significance. See Table 2 for values and statistics. Behavior was assessed via liquid thrashing assays. C. elegans homozygous for a mutant allele in a candidate gene and the tau transgene were compared to tau transgenic C. elegans. At least 15 animals were assessed per strain. Student's t-tests were used to determine significance for each allele. Genes were considered suppressors or enhancers only if all alleles of the gene tested caused significant effects on behavior. Figure S1 . Loss of bas-1 does not significantly alter swimming behavior in wild-type C. elegans.
[A] Effect of bas-1(ad446) on liquid thrashing rate of wild-type (N2) worms.
[B] Effect of bas-1(tm351) on liquid thrashing rate of N2 worms. 4-day-old C. elegans were placed in M9 buffer and thrashes were counted for 1 minute. Experiments were performed 5 times for a total of 100 worms per group. Data is displayed as mean ± standard error (S.E.M.). Student's t-test was used to compare N2 to bas-1 worms. See Table 1 Table S5 . Comparison of swimming behavior of tgT337;bas-1(ad446);cat-2(e1112), tgT337;bas-1(ad446);cat-2(n4547), tgT337;bas-1(ad446);tph-1(n4622), and tgT337;bas-1(ad446);cat-4(e1141) worms to tau transgenic (tgT337) and tgT337;bas-1(ad446).
Strain
Thrashes/minute (average ± S.E.M.)
Comparison vs tgT337
Comparison vs tgT337;bas-1(ad446) tgT337
17.4 ± 1.3 X p < 0.0001 tgT337; bas- 1(ad446) 38.2 ± 2.0 p < 0.0001 X tgT337; bas-1(ad446); cat-2(e1112)
28.2 ± 1.7 p < 0.0001 p = 0.0003 tgT337; bas-1(ad446); cat-2(n4547) 26.2 ± 1.6 p = 0.002 p < 0.0001 tgT337; bas-1(ad446); tph-1(n4622) 29.3 ± 1.8 p < 0.0001 p = 0.0018 tgT337; bas-1(ad446); cat-4(e1141) 21.4 ± 1.7 p = 0.59 p < 0.0001 4-day-old C. elegans were placed in M9 buffer and thrashes were counted for 1 minute, Experiments were performed 7 times for a total of 100 worms per group. Data was analyzed by one-way ANOVA and multiple pairwise comparisons (Sidak's) performed between strains. 39.3 ± 2.0 p < 0.0001 p = 0.17 4-day-old C. elegans were placed in M9 buffer and thrashes were counted for 1 minute. Experiments were performed 5 times for a total of 100 worms per group. Data was analyzed by two-way ANOVA and multiple pairwise comparisons (Tukey's) performed between strains.
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